ArticlePloS one2026
Impact of a pharmacist-led optimization strategy for cerebrovascular pharmacotherapy beyond recanalization in acute ischemic stroke: A pre- and post-intervention study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePolypharmacy involving cerebrovascular agents is common in acute ischemic stroke, but its clinical and economic value remains unclear. This study evaluated the impact of a pharmacist-led Stroke Pharmacotherapy Optimization Strategy (SPOS) in reducing polypharmacy, drug-related costs, and adverse events while preserving neurological recovery.
methodsA pre-post study was conducted at a tertiary hospital from June 2024 to April 2025. The control cohort included patients admitted from June to October 2024, and the SPOS cohort included patients admitted from December 2024 to April 2025. SPOS followed the "3-2-1" principle (≤3 non-recanalization cerebrovascular drugs, [NR-CVDs]; ≤ 2 cerebrovascular-related traditional Chinese medicines, [CR-TCMs]) to simplify pharmacotherapy and integrated pharmacist-led medication monitoring, patient education, and individualized adjustments.
resultsA total of 416 patients were included (204 control, 212 SPOS). The SPOS group received significantly fewer NR-CVDs (SPOS group: 3.03 ± 1.18 vs control group: 4.62 ± 1.15; P < 0.001) and CR-TCMs (SPOS group: 1.04 ± 0.90 vs control group: 1.93 ± 1.02; P < 0.001), without difference in ΔNIHSS or overall neurological recovery. Although the length of hospital stay was similar between groups, total hospitalization costs, drug costs, and the proportion of drug-related expenditures were markedly reduced in the SPOS group (all P < 0.001), and the incidence of adverse events was lower in the SPOS group (P = 0.034), with no evident safety signal associated with medication simplification during hospitalization.
conclusionsPharmacist-led SPOS in acute ischemic stroke reduced unnecessary cerebrovascular medications and drug costs and was associated with a lower incidence of in-hospital adverse events, without compromising short-term neurological recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.